On March 5, Ge Longhui Pharmaceutical (600513.SH) released its 2023 annual report. Operating revenue was 2.174 billion yuan, up 11.20% year on year, net profit of 135 million yuan, down 4.5% year on year, after deducting non-net profit of 116 million yuan, down 13.27% year on year, and basic earnings per share of 0.47 yuan. It is proposed to distribute a cash dividend of 1.5 yuan for every 10 shares to all shareholders.
联环药业(600513.SH)：2023年净利润同比下降4.5% 拟10派1.5元
Lianhuan Pharmaceutical (600513.SH): Net profit in 2023 fell 4.5% year-on-year, and plans to pay 10 to 1.5 yuan
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.